Table 4.
Demographic and clinical characteristics of SLE patients with and without pulmonary fibrosis
| SLE with pulmonary fibrosis (n = 17) | SLE without pulmonary fibrosis (n = 17) | |
|---|---|---|
| Age (mean ± SD) | 36.1 ± 11.2 | 37.2 ± 11.5 |
| Smoker | 2 (11.8 %) | 2 (11.8 %) |
| Gender | ||
| Female | 16 (94.1 %) | 15 (88.2 %) |
| Male | 1 (5.9 %) | 2 (11.8 %) |
| SLAM score median (range) | 8.00 ± 3.17 | 6.00 ± 2.31 |
| Active | 5 (29.4 %) | 1 (5.9 %) |
| Inactive | 12 (70.6 %) | 16 (94.1 %) |
| ANA ≥ 1:160 | 17 (100 %) | 17 (100 %) |
| Positive anti-dsDNA | 2 (11.8 %) | 2 (11.8 %) |
| Anti-RNP | 0 (0 %) | 0 (0 %) |
| P/MP therapy | 8 (47 %) | 8 (47 %) |
| NSAID therapy | 5 (29.4 %) | 4 (23.5 %) |
| Immunosuppressive (MM, A) therapy | 2 (11.8 %) | 2 (11.8 %) |
| Fever | 1 (5.9 %) | 2 (11.8 %) |
| Skin and mucous membrane lesion | 9 (52.9 %) | 6 (35.3 %) |
| Arthritis | 7 (41.2 %) | 4 (23.5 %) |
| Renal active disorders | 2 (11.8 %) | 1 (5.9 %) |
| Cardiac disorders | 1 (5.9 %) | 0 (0 %) |
| Neuropsychiatric disorders | 6 (35.3 %) | 5 (29.4 %) |
| Gastrointestinal disorders | 4 (23.5 %) | 2 (11.8 %) |
| Lymphadenopathy | 0 (0 %) | 0 (0 %) |
| Anemia (Hb <12 g/dl) | 3 (17.6 %) | 3 (17.6) |
| Leucopenia (WBC <3.5 cc mm) | 5 (29.4 %) | 2 (11.8 %) |
| Thrombocytopenia (<150,000 cc mm) | 2 (11.8 %) | 1 (5.9 %) |
| ESR >25 mm/h | 6 (35.3 %) | 3 (17.6 %) |
A azathioprine, ANA antinuclear antibody, anti-ds DNA anti-double stranded DNA, anti-RNP antibody to ribonucleoprotein, ESR erythrocyte sedimentation rate, MM mycophenolate mofetil, MP methylprednisolone, NSAID non-steroidal anti-inflammatory drug, P prednisone, SLAM systemic lupus activity measure